Ironwood Pharmaceuticals (IRWD) Interest & Investment Income (2010 - 2026)

Ironwood Pharmaceuticals has reported Interest & Investment Income for 17 years, with the latest figure at $1.7 million in Q1 2026.

• Quarterly Interest & Investment Income rose 95.4% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 17.68% YoY) and the FY2025 annual result came in at $4.1 million, down 8.77% from the prior year.
• Interest & Investment Income grew to $1.7 million in Q1 2026 per IRWD's latest filing, from $1.5 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $8.8 million in Q2 2023 and troughed at $230000.0 in Q1 2022.
• A 5-year average of $2.3 million and a median of $1.2 million in 2023 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2023 and 2024: Interest & Investment Income soared 3061.74% in 2023, then slumped 84.37% in 2024.
• Over 5 years, Interest & Investment Income stood at $5.4 million in 2022, then tumbled by 78.08% to $1.2 million in 2023, then tumbled by 34.84% to $778000.0 in 2024, then surged by 87.53% to $1.5 million in 2025, then climbed by 16.38% to $1.7 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $1.7 million, $1.5 million, and $930000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.